Novel anti-cancer agents in development: Exciting prospects and new challenges

Cancer Treatment Reviews

Volumn 25, Issue 5, 1999, Pages 301-312

  Seymour, L ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Epidermal growth factor receptor; Matrix metalloproteinase inhibitors; Novel; Nucleoside analogues; Phase I; Phase II; Signal transduction inhibition

Indexed keywords

4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 DEDIMETHYLAMINOSANCYCLINE; 4 [4,4 (CHLOROPHENYL)PHENYL] 4 OXO (PHENYLTHIOMETHYL)BUTANOIC ACID; A 177430; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BATIMASTAT; BRYOSTATIN; CGP 59326; CGP 69846A; CGS 27023A; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIN DEPENDENT KINASE; DEHYDRODIDEMNIN B; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLAVOPIRIDOL; FLUOROURACIL; GEFITINIB; ISIS 3521; MARIMASTAT; MATRIX METALLOPROTEINASE; MONOCLONAL ANTIBODY; PRINOMASTAT; PROTEIN KINASE C; PROTEIN TYROSINE KINASE; REBIMASTAT; SCH 66366; TROXACITABINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; [6,7 BIS(2 METHOXY ETHOXY)QUINAZOLINE 4 YL](3 ETHYNYLPHENYL)AMINE;

ANEMIA; CANCER; CANCER CONTROL; CARDIOTOXICITY; CLINICAL TRIAL; DRUG DESIGN; DRUG HYPERSENSITIVITY; DRUG TARGETING; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION; HEADACHE; HUMAN; HYPOTENSION; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; METHODOLOGY; MUSCULOSKELETAL DISEASE; ONCOGENE RAS; OVARY CANCER; PANCREAS CANCER; PRENYLATION; PROSTATE CANCER; RASH; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA;

EID: 0032706396     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1053/ctrv.1999.0134     Document Type: Review

References (105)

1. Zee B., Melynychuk D., Dancey J., Eisenhauer E. Multinomial phase II cancer trials incorporating response and early progression. J Biopharm Stats. 9:1999;351-363.
2. Lombard M. A., Wallace T. L., Kubicek M. F., Petzold G. L., Mitchell M. A., Hendges S. K., Wilks J. W. Synthetic matrix metalloproteinase inhibitors and tissue inhibitor of metalloproteinase (TIMP-2), but not TIMP-1, inhibit shedding of Tumor Necrosis Factor-α receptors in a human colon adenocarcinoma (Colo 205) cell line. Cancer Res. 58:1998;4001-4007.
3. Albanell J., Codony J., Arribas J., Baselga J. Inhibition of HER2 extracellular domain shedding by metalloprotease inhibitors and by Herceptin in breast cancer cells. Proc Am Soc Clin Oncol. 18:1999;A2381.
4. Wojtowicz-Praga S., Dickson R. B., Hawkins M. J. Matrix metalloproteinase inhibitors. Invest New Drugs. 15:1997;61-75.
5. Michael M., Babic B., Khoka R., Tsao M., Ho J., Pintilie M., Leco K., Chamberlain D., Shepherd F. A. Expression and prognostic significance of metalloproteinases and their tissues inhibitors in patients with small cell lung cancer. J Clin Oncol. 17:1999;1802-1808.
6. Rasmussen H., Rugg T., Brookes C., Baillet M., Harris J. First placebo controlled safety review of marimastat: a potential new therapeutic class. Proc Am Soc Clin Oncol. 18:1999;A743.
7. Nemunaitis J., Poole C., Primrose J., Rosemurgy A., Malfetano J., Brown P., Berrington A., Cornish A., Lynch K., Rasmussen H., Kerr D., Cox D., Millar A. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Clin Cancer Res. 4:1998;1101-1109.
8. Primrose J. N., Bleiberg H., Daniel F., Van Belle S., Mansi J. L., Seymour M., Johnson P. W., Neoptolemos J. P., Baillet M., Barker K., Berrington A., Brown P. D., Millar A. W., Lynch K. P. Marimastat in recurrent colorectal cancer: exploratory evaluation of biological activity by measurement of carcinoembryonic antigen. Br J Cancer. 79:1999;509-514.
9. Rosemurgy A., Buckels J., Charnley R., Winston R., Steward W., Staddon A., Curtis L., Rugg T., Rasmussen H. A randomized study comparing marimastat to gemcitabine as first line therapy in patients with non-resectable pancreatic cancer. Proc Am Soc Clin Oncol. 18:1999;A1005.
10. Hibner B., Bull C., Flynn C., Eberwein D., Garrison T., Casazza A., Carter C., Gibson N. Activity of the matrix metalloproteinase inhibitor BAY12-9566 against murine subcutaneous and metastatic in vivo models. Ann Oncol. 9:1998;A283.
11. Seymour L., Grochow L., Eckhardt G., Erlichman C., Hirte H., Goel R., Humphrey R., Elias I. Clinical and pharmacokinetic results of four phase I studies of the second-generation matrix metalloproteinase inhibitor BAY 12-9566, a non-peptidic biphenyl inhibitor of MMPs 2,3, and 9. Ann Oncol. 9:1998;125.
12. Goel R., Hirte H., Major P., Waterfield B., Holohan S., Bennett K., Elias I., Seymour L. Clinical pharmacology of the metalloproteinase inhibitor BAY 12-9566 in cancer patients. Proc Am Soc Clin Oncol. 18:1999;160a.
13. Leppert D., Waubant E., Galardy R., Bunnett N. W., Hauser S. L. T cell gelatinases mediate basement membrane transmigration in vitro. J Immunol. 154:1995;4379-4389.
14. Ries C., Loher F., Zang C., Ismair M. G., Petrides P. E. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes. Clin Cancer Res. 5:1999;1115-1124.
15. Chouinard E., Goel R., Hirte H., Stewart D., Hurak S., Waterfield B., Matthews S., Elias I., Seymour L. A phase I interaction study between BAY 12-9566 and doxorubicin in cancer patients. Proc Am Assoc Cancer Res. 40:1999;A560.
16. Tolcher A., Rowinsky E. K., Rizzo J., Britten C., Siu L., Humphrey R., Smetzer L., Sorenson M., Von Hoff D. D., Eckhardt S. G. A phase I and pharmacokinetic study of the oral matrix metalloproteinase inhibitor BAY 12-9566 in combination with paclitaxel and carboplatin. Proc Am Soc Clin Oncol. 18:1999;A617.
17. Hande K., Wilding G., Ripple G., Fry J., Arzoomanian R., Dixon M., Yuen G., Collier M. A phase I study of AG 3340, a matrix metalloprotease inhibitor, in patients having advanced cancer. Ann Oncol. 9:1998;A279.
18. Collier M., Shepherd F., Ahmann R., Keller M. R., Michelson G., Paradiso L., Clendeninn N. A novel approach to studying the efficacy of AG 3340, a selective inhibitor of matrix metalloproteases (MMP's). Proc Am Soc Clin Oncol. 18:1999;A1861.
19. Shalinsky D., Brekken J., Zou H., Bloom L., McDermott C., Appelt A., Varki N. M. AG 3340, a novel MMP inhibitor has a superior therapeutic index to carboplatin in nude mice bearing chemoresistant human MV522 lung cancer tumors. Ann Oncol. 9:1998;A278.
20. Marshall C. J. Opportunities for pharmacological intervention in the ras pathway. Ann Oncol. 6:1995;S63-67.
21. Baselga J., Mendelsohn J. The epidermal growth factor receptor as a target for therapy in breast carcinoma. Br Cancer Res Treat. 29:1994;127-138.
22. Shawver L., Lipson K., Fong T., McMahon G., Plowman G., Strawn M. Receptor tyrosine kinases as targets for inhibition of angiogenesis. Drug Discovery Today. 2:1997;50-63.
23. Morgan D. Cyclin dependent kinases: engines clocks and microprocessors. Annu Rev Cell Dev Biol. 13:1997;261-291.
24. Lundberg A., Weinberg R. Control of the cell cycle and apoptosis. Eur J Cancer. 35:1999;531-539.
25. Hall M., Peters G. Genetic alterations of cyclins, cyclin dependent kinases and cdk inhibitors in human cancer. Adv Cancer Res. 68:1996;67-108.
26. Lonardo F., Rusch V., Langenfeld J., Dmitrovsky E., Klimstra D. Overexpression of cyclins D1 and E is frequent in bronchial preneoplasia and precedes squamous cell carcinoma development. Cancer Res. 59:1999;2470-2476.
27. Levitzki A., Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science. 267:1995;1782-1787.
28. Fry, D. Bridges, A. Denny, W. Doherty, A. Gries, K. Hicks, J. Hook, K. Keller, P. Leopold, W. Loo, J. McNamara, D. Nelson, J. Sherwood, V. Smaill, J. Trumpp-Kallmeyer, S. Dobrusin, E. Specific irreversible inactivation of the epidermal growth factor inhibitor and erbB2 by a new class of tyrosine kinase inhibitor. Proc Natl Acad Sci, 95(20), 12022, 12027.
29. Sun L., Tran N., Tang F., App H., Hirth P., McMahon G., Tang C. Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases. J Med Chem. 41(14):1998;2588-2603.
30. Mendelsohn J., Shin D., Donato N., Khuri F., Radinsky R., Glisson B., Shin H., Metz E., Pfister D., Perez-Soler R., Lawhorn K., Matsumoto T., Gunnett K., Falcey J., Waksal H., Hong W. A phase I study of chimerized anti-epidermal growth factor receptor monoclonal antibody, C225 in combination with cisplatin in patients with recurrent head and neck squamous cell carcinoma. Proc Am Soc Clin Oncol. 18:1999;A1502.
31. Gunnett K., Motzer R., Amato R., Todd M., Poo W-J., Cohen R., Baselga J., Cooper M., Robery F., Falcey J., Waksal H. Phase II study of anti-epidermal growth factor receptor antibody C225 alone in patients with metastatic renal cell carcinoma. Proc Am Soc Clin Oncol. 18:1999;A1309.
32. Norton L., Slamon D., Leyland-Jones B., Wolter J., Fleming T., Eirmann W., Baselga J., Mendelsohn J., Bajamonde A., Ash M., Shak S. Overall survival advantage to simultaneous chemotherapy plus the humanized anti-HER2 monoclonal antibody herceptin in HER-2 overexpressing metastatic breast cancer. Proc Am Soc Clin Oncol. 18:1999;A483.
33. Ciardiello F., Bianco R., Damiano V., De Lorenzo S., Pepe S., De Placido S., Fan Z., Mendelsohn J., Bianco R., Torotora G. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res. 4:1999;909-916.
34. Geiger T., Muller M., Monia B. P., Fabbro D. Antitumor activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice. Clin Cancer Res. 3(7):1997;1179-1185.
35. Mani S., Shulman K., Kunkel K., Geary R., Holmund J. T., Dorr A., Rudin C. M., Ratain M. J. Phase I trial of protein kinase C antisense oligonucleotide (ISIS3521) with 5-fluorouracil and leucovorin in patients with advanced cancer. Proc Am Soc Clin Oncol. 18:1999;A608.
36. Sikic B., Yuen A., Advani R., Fisher G., Halsey J., Geary R., Kwoh T., Holmund J., Dorr A. A phase I trial of ISIS3521, an antisense inhibitor of protein kinase C-alpha, combined with carboplatin and paclitaxel in patients with cancer. Proc Am Soc Clin Oncol. 18:1999;A1718.
37. Ullrich A., Coussens L., Hayflick J. S., Dull T. J., Gray A., Tam A. W., Lee J., Yarden Y., Liebermann T. A., Schlessinger J. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A341 epidermoid carcinoma cells. Nature. 309:1984;418-425.
38. Peles E., Yarden Y. Neu and its ligands: from an oncogene to a neural factor. Bioessays. 15:1993;815-824.
39. Nicholson R. I., McClelland R. A., Finlay P., Eaton C. L., Gullick W. J., Dixon A. R., Robertson J. F., Ellis I. O., Blamey R. W. Relationship between EGF-R, c-erb-B-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. Eur J Cancer. 29A:1993;1018-1023.
40. Rude Voldberg B., Damstrup L., Spang-Thomsen M., Skovgaard Poulsen H. Epidermal growth factor receptor and EGF-R mutations, function and possible role in clinical trials. Ann Oncol. 8:1997;1197-1206.
41. Woodburn J., Barker A., Gibson K., Ashton S., Wakeling A., Curry B., Scarlett L., Henthorn L. ZD1839, an epidermal growth factor tyrosine kinase inhibitor selected for clinical development. Proc Am Assoc Cancer Res. 38:1997;A4251.
42. Hammond L., Ranson M., Ferry D., Kris M., Kelly H., Ochs J., Averbuch S., Rowinsky E. ZD1839 an oral epidermal growth factor receptor tyrosine kinase inhibitor: first phase I, pharmacokinetic results in patients. Proc Am Soc Clin Oncol. 18:1999;A1500.
43. Bos M., Mendelsohn J., Kim Y-M., Albanell J., Fry D. W., Baselga J. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner. Clin Cancer Res. 3:1997;2099-2106.
44. Moyer J., Barbacci E., Iwata K., Arnold L., Boman B., Cunningham A., DiOrio C., Doty J., Morin M., Moyer M., Neveu M., Pollack V., Pustilnik L., Reynolds M., Sloan D., Theleman A., Miller P. Induction of apoptosis and cell cycle arrest by CP358774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 57:1997;4838-4848.
45. Siu L., Hidalgo M., Nemumaitis J., Rizzo J., Moczygemba J., Eckhardt S., Tolcher A., Smith L., Hammond L., Blackburn A., Tensfeldt T., Silberman S., Von Hoff D., Rowinsky E. Dose and schedule duration escalation of the epidermal growth factor receptor tyrosine kinase inhibitor CP358774: a phase I and pharmacokinetic study. Proc Am Soc Clin Oncol. 18:1999;A1498.
46. Karp D., Silberman S., Csudae R., Wirth F., Gaynes L., Posner M., Bubley G., Koon H., Bergman M., Huang M., Schnipper L. Phase I dose escalation study of epidermal growth factor receptor tyrosine kinase inhibitor CP358774 in patients with advanced solid tumors. Proc Am Soc Clin Oncol. 18:1999;A1499.
47. Chen H., Ness E., Marshall J., Martin R., Dvorchik B., Rizvi N., Marquis J., Dahut W., Hawkins M. Phase I trial of a second generation oligonucleotide (GEM231) targeted at type I protein kinase A in patients with refractory solid tumors. Proc Am Soc Clin Oncol. 18:1999;A610.
48. Kuss B., Cotter F. Antisense - time to shoot the messenger. Ann Oncol. 10:1999;495-503.
49. Flanagan W. M. Antisense comes of age. Cancer and Metast Rev. 17:1998;169-176.
50. Wang H., Rapp U., Reed J. Bcl-2 targets the protein kinase raf-1 to mitochondria. Cell. 87:1996;629-638.
51. Holmlund J., Nemunaitis J., Schiller J., Dorr A., Kisner D. Phase I trial of c-raf-kinase antisense oligonucleotide ISIS 5132 (CGP 69846A) by 21-day continuous intravenous infusion in patients with advanced cancer. Proc Am Soc Clin Oncol. 17:1998;A811.
52. Stevenson J., Yao K-S., Gallagher M., Friedland D., Mitchell E., Cassella A., Monia B., Kwoh T. J., Yu R., Dorr F. A., O'Dwyer P. Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 kinase antisense oligonucleotide ISIS 5132 (CGP 69846A). J Clin Oncol. 17:1999;222-2236.
53. Holmund J., Rudin C., Mani S., Fleming G., Stadler W., Kunkel K., Kwoh T., Geary R., Dorr A., Ratain M. Phase I trial of ISIS 5132/ODN698A, a 20-mer phosphorothiate antisense olignonucleotide inhibitor of c-raf kinase, administered by a 24 hour weekly intravenous infusion to patients with advanced cancer. Proc Am Soc Clin Oncol. 18:1999;A605.
54. Sikic B., Yuen A., Advani R., Halsey J., Fisher G., Holmlund J., Dorr A. Antisense oligonucleotide therapy targeted to protein kinase c-alpha (ISIS 3521) by 21-day continuous infusion: results of the phase I trial and activity in ovarian carcinomas. Proc Am Soc Clin Oncol. 17:1998;A1654.
55. Advani R., Fischer G., Grant P., Yuen A., Holmlund J., Kwoh T., Dorr A., Geary R., Sikic B. A phase I trial of an antisense oligonucleotide targeted to protein kinase C (ISIS 3521/ISI641A) delivered as a 24-hour continuous infusion. Proc Am Soc Clin Oncol. 18:1999;A609.
56. Thijsen S., Schurrhuis G., van Oostveen J., Theijsmeijer A., van der Hem K., Odding J., Drager A., Ossenkoppele G. Effects of bryostatin-1 on chronic myeloid leukaemia-derived haematopoietic progenitors. Br J Cancer. 79:1999;1406-1412.
57. Spitaler M., Utz I., Hilbe W., Hofmann J., Grunicke H. PKC-independent modulation of multidrug resistance in cells with mutant (V185) but not wild-type (G185) p-glycoprotein by bryostatin. Biochem Pharm. 56 (7):1998;861-869.
58. Varterasian M., Mohammad R., Eilender D., Hulburd K., Rodriguez D., Pemberton P., Pluda J., Dan M., Pettit G., Chen B., Al-Katib A. Phase I study of bryostatin 1 in patients with relapsed non-Hodgkins lymphoma and chronic lymphocytic leukemia. J Clin Oncol. 16:1998;56-62.
59. Jayson G. C., Crowther D., Prendiville J., McGown A. T., Scheid C., Stern P., Young R., Brenchley P., Chang J., Owens S. A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion. Br J Cancer. 72:1995;461-468.
60. Propper D., Macauley V., O'Byrne K., Braybrooke J., Wilner S., Ganesan T., Talbot D., Harris A. A phase II study of bryostatin 1 in metastatic malignant melanoma. Br J Cancer. 78:1998;1337-1341.
61. Tozer R., Burdette-Radoux S., Belanger K., Davis M., Lohmann R., Rusthoven J., Wainman N., Seymour L. NCIC CTG randomized phase II study of two schedules of bryostatin-1 in patients with advanced malignant melanoma. Proc Am Soc Clin Oncol. 18:1999;A2052.
62. Bedikian A., Plager C., Eton O., Ellerhorst J., Smith T. Phase II trial of bryostatin-1 in patients with melanoma. Proc Am Soc Clin Oncol. 18:1999;A2051.
63. Kaubisch A., Kelsen D., Saltz L., Kemeny N., O'Reilly E., Ilson D., Endres S., Barazzuol J., Schwartz G. A phase I trial of weekly sequential bryostatin-1 and paclitaxel in patients with advanced solid tumors. Proc Am Soc Clin Oncol. 18:1999;A639.
64. Walker D. H. Small-molecule inhibitors of cyclin-dependent kinases: molecular tools and potential therapeutic. Curr Topics Microbiol Immunol. 227:1998;149-165.
65. Schrump D. S., Matthews W., Chen G. A., Mixon A., Altorki N. K. Flavopiridol mediates cell cycle arrest and apoptosis in esophageal cancer cells. Clin Cancer Res. 4(11):1998;2885-2890.
66. Senderowicz A., Headlee D., Stinson S., Lush R., Kalil N., Villaba L., Hill K., Steinberg S., Figg W., Tompkins A., Arbuck S., Sausville E. Phase I trial of continuous infusion flavopiridol, a novel cyclin dependent kinase inhibitor in patients with refractory neoplasms. J Clin Oncol. 16:1998;2986-2999.
67. Schwartz G., Kaubisch A., Salyz L., Ilson D., O'Reilly E., Barazzuol J., Endres S., Soltz M., Tong W., Spriggs D., Kelsen D. Phase I trial of sequential paclitaxel and the cyclin dependent kinase inhibitor flavopiridol. Proc Am Soc Clin Oncol. 18:1999;A614.
68. Shapiro G., Patterson A., Lynch C., Lucca J., Anderson I., Boral A., Elias A., Lu H., Salgia R., Skarin A., Panek-Clark C., McKenna R., Rabin M., Vasconcelles M., Eder P., Supko Supko J., Lynch T., Rollins B. A phase II trial of flavopiridol in patients with stage IV non-small cell lung cancer. Proc Am Soc Clin Oncol. 18:1999;A2013.
69. Bennett P., Mani S., O'Reilly S., Wright J., Schilsky R., Vokes E., Grochow L. Phase II trial of flavopiridol in metastatic colorectal cancer: preliminary results. Proc Am Soc Clin Oncol. 18:1999;A1065.
70. Senderowicz A., Headlee D., Lush R., Arbuck S., Bauer K., Figg W., Murgo A., Inoue K., Kobashi S., Kuwabara T., Sausville E. Phase I Trial of Infusional UCN-01, a Novel Protein Kinase Inhibitor, in Patients with Refractory Neoplasms. Proc Am Soc Clin Oncol. 18:1999;A612.
71. Fuse E., Tanii H., Kurata N., Kobayashi H., Shimada Y., Tamura T., Sasaki Y., Tanigawara Y., Lush R. D., Headlee D., Figg W. D., Arbuck S. G., Senderowicz A. M., Sausville E. A., Akinaga S., Kuwabara T., Kobayashi S. Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein. Cancer Res. 58:1998;3248-3253.
72. Beaupre D., Kurzrock R. RAS and leukemia: from basic mechanisms to gene-directed therapy. J Clin Oncol. 17:1999;1071-1079.
73. Gordon M., Sandler A., Holmlund J., Dorr A., Battiato L., Fife K., Geary R., Kwoh T., Sledge G. A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, administered by a 24-hour weekly infusion to patients with advanced cancer. Proc Am Soc Clin Oncol. 18:1999;A604.
74. Gibbs J., Oliff A. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. Annu Rev Pharmacol Toxicol. 37:1997;143-166.
75. Lebowitz P., Prendergast G. Non-ras targets for farnesyltransferase inhibitors: focus on Rho. Oncogene. 17:1998;1439-1447.
76. Eskens F., Awada A., Verweij J., Cutler D., Hanauske A., Piccart M. Phase I and pharmacologic study of continuous daily oral SCH66336, a novel farnesyltransferase inhibitor in patients with solid tumors. Proc Am Soc Clin Oncol. 18:1999;A600.
77. Adjei A., Erlichman C., Davis J., Reid J., Sloan J., Statkevich P., Zhu Y., Marks R., Pitot C., Goldberg R., Hanson L., Alberts S., Cutler D., Kaufman S. A phase I and pharmacologic study of the farnesyltransferase inhibitor SCH66336 in patients with locally advanced or metastatic cancer. Proc Am Soc Clin Oncol. 18:1999;A598.
78. Hurwitz H., Colvin M., Petros W., Williams R., Conway D., Adams D., Casey P., Calzetta A., Mastorides P., Statkevch P., Cutler D. Phase I and pharmacokinetic study of SCH66336, a novel FPTI using a 2-week on, 2-week off schedule. Proc Am Soc Clin Oncol. 18:1999;A599.
79. Giles F. J., Cortes J. F., Beran M., Estey E., Proulx L., Jolivet J., Bivins C., Rios M. D., Kantarjian H. Phase I study of BCH4556 in patients with advanced leukemia. Proc Am Soc Clin Oncol. 18:1999;A103.
80. Kadhim S. A., Bowlin T. L., Waud W. R., Angers E. G., Bibeau L., DeMuys J-M., Bednarski K., Cimpoia A., Attardo G. Potent antitumor activity of a novel nucleoside analogue, BCH-4556 (β-L-dioxolane-cytidine) in human renal cell carcinoma xenograft models. Canc Res. 57:1997;4803-4810.
81. Stephenson J., Baker S. D., Johnson T., Simmons C., Smith L., Hunt W., Deforges C., Proulx L., Jolivet J., Hidalgo M., Eckhardt S. G., Hammond L., Diab S., Smith L., Von Hoff D., Rowinsky E. Proc Am Soc Clin Oncol. 18:1999;A761.
82. Canova A., Yee L., Baker S., Sarid R., Desforges C., Jolivet J., Hunt W., Tiedemann D., Lillo R., Gaskins A., Chu E. A phase I and pharmacokinetic study of b-L-dioxalo-cytidine (BCH-4556) administered weekly for three weeks every 28 days. Proc Am Soc Clin Oncol. 18:1999;A759.
83. Moore, M. Belanger, K. Jolivet, J. Baker, S. Wainman, N. Seymour, L. NCIC CTG IND 103: A Phase I And Pharmacokinetic (PK) Study Of The Novel L-Nucleoside Analog Troxacitabine (BCH-4556) Given Every 21 Days. Eur J Cancer, ECCO 1999, A1140.
84. Belanger K., Moore M., Siu L., Dionne J., McLean M., Jolivet J., Wainman N., Seymour L. A phase I study of the I-nucleoside analogue B-L-dioxolane-cytidine (BCH-4556) given as a 30-minute infusion every 21 days. Proc Am Soc Clin Oncol. 18:1999;A760.
85. Baker S. D., Stephenson J., Goetz J., Belanger K., Moore M., Seymour L., Yee L., Hunt W., Jolivet J., Rowinsky E. Determinants affecting b-L-dioxolane-cytidine (BCH-4556) exposure and relationship with toxicity in phase I trials. Proc Am Soc Clin Oncol. 18:1999;A758.
86. Shin D. M., Holoye P. Y., Murphy W. K., Forman A., Papasozomenos S. C., Ki Hong W., Raber M. Phase I/II clinical trial of didemnin B in non-small cell lung cancer: neuromuscular toxicity is dose limiting. Cancer Chemother Pharmacol. 29:1991;145-149.
87. Mastbergen S., Henrar R., Faircloth G., Geldof A. Cytotoxicity and neurocytotoxicity of aplidine, a new marine anticancer agent evaluated using in vitro assays. Ann Oncol. 9:1998;A131.
88. Depenbrock H., Peter R., Faircloth G. T., Manzanares I., Jimeno J., Hanauske A. R. In-vitro activity of aplidine, a new marine derived anti-cancer compound, on freshly explanted clonogenic human tumor cells and haematopoietic precursor cells. Br J Cancer. 78:1998;739-744.
89. Eckhardt S., Pluda J. Development of angiogenesis inhibitors for cancer therapy. Invest New Drugs. 15:1997;1-3.
90. Eisenhauer E. Phase I and II trials of novel anti-cancer agents: endpoints, efficacy and existentialism. Ann Oncol. 9:1998;1047-1052.
91. Eatock M., Cassidy J., Johnson J., Morrison R., Devlin M., Owen S., Choi L., Mather R., Twelves C. A phase I study of the matrix metalloproteinase inhibitor MM1270 (previously termed CGS27023A) with 5FU and folinic acid. Proc Am Soc Clin Oncol. 18:1999;A803.
92. Albert D. H., Tapang P., Kherzai A. W., Nuss M. E., Luo Y., Steinman D. H., Marcotte P. A., Magoc T. J., Bouska J., Davidsen S. K., Morgan D. W. Efficacy of a synthetic matrix metalloproteinase inhibitor A-177430 in a subcutaneous melanoma and an orthotopic brain tumor model. Proc Am Ass Cancer Res. 40:1999;A2623.
93. Traxler P., Furet P., Mett H., Buchdunger E., Meyer T., Lydon N. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R. J Pharmacie de Belgique. 52:1997;88-96.
94. Pfister D., Lipton A., Belt R., Motzer R., Winston C., Metz E., Sherman E., Curnow R. A phase I trial of the epidermal growth factor receptor directed bispecific antibody MDX-447 in patients with solid tumors. Proc Am Soc Clin Oncol. 18:1999;A1667.
95. Yang X-D., Jia X., Corvalan J., Wang P., Jakobovits A., Davis C. Potent anti-tumor activity of ABX-EGF a fully human monoclonal antibody to the epidermal growth factor receptor. Proc Am Soc Clin Oncol. 18:1999;A1766.
96. Malkin M. G., Mason W. P., Lieberman F. S., hannah A. L. Phase I study of SU101 a novel signal transduction inhibitor in recurrent malignant glioma. Proc Am Soc Clin Oncol. 16:1997;A1371.
97. Bruker B., Sawyers C., Talpaz M., Resta D., Peng B., Ford J. Phase I trial of a specific abl tyrosine kinase inhibitor CGP57148 in interferon refractory chronic myelogenous leukemia patients. Proc Am Soc Clin Oncol. 18:1999;A24.
98. Klohs W., Steinkampf R., Driscoll D., Klutchko S., Hamby J., Lu G., Vincent P., Roberts B., Elliot W. Characterization of PDGF-R tyrosine kinase inhibitors in vitro and in vivo. Proc Am Assoc Cancer Res. 38:1997;A4244.
99. Kraker A. J., Moore C. W., Amar A. M., Shen C. S., Nelson J., Slintak V., Fry D. W., Lu G., Panek R., Klutchko S., Hamby J. Cytotoxicity and phosphotyrosine effects of c-src kinase inhibition by substituted pyridopyrimidine tyrosine kinase inhibitors in human colon carcinoma cell lines. Proc Am Assoc Cancer Res. 38:1997;A4247.
100. Rosen L., Mulay M., Mayers A., Kabbinavar F., Rosen P., Cropp G., Hannah A. Phase I dose escalating trial of SU5416, a novel angiogenesis inhibitor in patients with advanced malignancies. Proc Am Soc Clin Oncol. 18:1999;A618.
101. Fong A., Shawver L., Sun L., Tang C., App H., Powell J., Kim Y., Schrek R., Wang X., Risau W., Ullrich A., Hirth P., McMahon G. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization and growth of multiple tumor types. Canc Res. 59:1999;99-106.
102. Xu L., Herrera C., Yoneda J., Wood J. M., Fidler I. J. Therapy of VEGF-dependent human ovarian carcinoma by oral administration of CGP79787, an inhibitor of the VEGF receptor tyrosine kinase. Proc Am Assoc Cancer Res. 40:1999;A3020.
103. Reese D., Frohlich M., Bok R., Corry M., Novotny W., Homgren E., Small E. A phase II trial of humanized monoclonal anti-vascular endothelial growth factor in hormone refractory prostate cancer. Proc Am Soc Clin Oncol. 18:1999;A1355.
104. Britten C. D., Rowinsky E., Yao S-L., Soignet S., Rosen N., Eckhardt S., Drengler R., Hammond L., Siu L., Smith L., McCreery H., Pezzulli S., Lee Y., Lobell R., Deutsch P., Von Hoff D., Spriggs D. The farnesyltransferase inhibitor L778123 in patients with solid tumors. Proc Am Soc Clin Oncol. 18:1999;A597.
105. Hudes G., Schol J., Baab J., Rogatko A., Bol C., Horak I., Langer C., Goldstein L., Szarka C., Meropol N., Weiner L. Phase I clinical and pharmacokinetic trial of the farnesyltransferase inhibitor R11577 on a 21-day dosing schedule. Proc Am Soc Clin Oncol. 18:1999;A601.